select trial semaglutide cardiovascular outcomes non-diabetic 2023 Beyond obesity: Novo's re-defines risk management Long-term kidney outcomes of semaglutide

Louis, United States Updates Copyright 2025 Dyka, Rodze, Rodze, ojko, Deptua, Grzywacz, Kraszewski, Barto, Martin, Deptua, Berry and Unwin

Retatrutide 10mg The 10mg vial format of retatrutide, Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist, offering greater dosing flexibility for metabolic research protocols targeting weight loss, insulin resistance, and hepatic fat

These trials are important because they show that semaglutide can help protect the heart, especially in people who already have risk factors like diabetes, high blood pressure, or high cholesterol

Injectable treatment may still be better for patients who prefer weekly administration, have complex morning medication needs, or are unlikely to manage fasting requirements consistently